Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Complete Title: SC-4002, An Open Label, Expanded Access Protocol Using 131I - Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Trial Phase: N/A

Investigator: Navin Pinto

Currently there is no known effective treatment for patients with advanced stage neuroblastoma, pheochromocytoma, or paraganglioma who have relapsed or not responded to standard therapy. In previous studies that used 131I-MIBG as a potential anti-cancer therapy, a decrease in the size of tumors was seen in some of the children and adults. This research study will continue to evaluate the side effects of 131I-MIBG when treating children and adults with neuroblastoma, pheochromocytoma, or paraganglioma. The 131I-MIBG compound is intended to work by selectively delivering the radioactive iodine to the tumor cells, which is then intended to result in their destruction. The purpose of this research study is to: - Make 131I-MIBG therapy available to patients with advanced neuroblastoma, pheochromocytoma, or paraganglioma - Further assess the side effects of 131I-MIBG therapy

Keywords:

Pediatric Cancers, Miscellaneous
Neuroblastoma
Solid Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms
Neuroectodermal Tumors
Neoplasms, Glandular and Epithelial
Neoplasms, Neuroepithelial
Pheochromocytoma
Paraganglioma

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Join a Clinical Trial

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Contact Us

If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.